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EFFECTS OF NORMOBARIC HYPEROXIA ON DIABETIC MACULAR EDEMA 





Purpose: Diabetic macular edema (DME) is the most common cause of vision 
loss in patients with diabetic retinopathy. This study aims to approach diabetic 
macular edema and diabetic retinopathy as ischemic conditions and explores a 
potential treatment through hyperoxia. The study measured changes in retinal 
thickness, visual acuity, and contrast sensitivity in subjects receiving normobaric 
oxygen.   
Methods: Fifty-one patients with diabetic macular edema at Beth Israel 
Deaconess Medical Center Eye Clinic (Boston, MA) received oxygen via a face 
mask at 5 liters per minute for 3 hours. Retinal thickness at the central subfield 
and maximal retinal thickness were measured using optical coherence 
tomography. Contrast sensitivity, best corrected visual acuity, and intraocular 
pressure were measured before and after oxygen as well.   
Results: Macular thickness from diabetic macular edema decreased by an 
average of 2.09% (p < .05) at the point of maximal thickness, and by 0.88% (p < 
.05) at the central subfield. Vision also improved by an average of 0.043 LogMAR 
units (p < .05). Changes in macular thickness and visual acuity were non-
	
	 vii 
significant in healthy control eyes that received oxygen. The results of hyperoxia 
on contrast sensitivity were indeterminate.  
Conclusions: We found that normobaric hyperoxia for 3 hours reduces macular 
thickness from diabetic macular edema and improves visual acuity. This study 
offers additional evidence that diabetic macular edema is an ischemic disorder 
and suggests that oxygen therapy may serve as an alternate or complimentary 
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Eye Anatomy and Physiology  
The human eye is the essential organ for vision. It has three 
distinguishable layers with the outermost being the cornea and sclera (Figure 1). 
The cornea, which is the most anterior portion, serves to refract light onto the 
retina and protect the eye from damage. Continuous with the cornea is the 
sclera, a connective tissue that protects and helps maintain the shape of the eye. 
Often known as the white of the eye, the sclera lies below a transparent layer 
called the conjunctiva (Willoughby et al., 2010). 
In the middle layer of the eye, there is the iris, ciliary body, and choroid. 
The iris controls the diameter of the pupil, which determines how much light 
reaches the retina. In order to control the focus of light, the ciliary body controls 
the shape of the lens, and consequently its power. While the ciliary body is 
connected to the iris on one end, it is connected to the choroid on the other. The 
choroid is a highly vascular layer that functions to supply the outer layers of the 
retina with oxygen and nutrients (Willoughby et al., 2010).  
Lastly, light is captured and processed by the innermost layer of the eye 
known as the retina. Between the light-sensitive photoreceptors of the retina and 
the blood supply of the choroid lies the retinal pigment epithelial (RPE) (Strauss, 
2018). Light that enters the eye passes through three transparent structures, 
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which are the aqueous, lens, and vitreous, before reaching the retina. The lens 














Figure 1. Structures of the eye. The three major layers of the eye are visible in 
the schematic including the outer sclera and cornea, middle choroidal layer, and 
inner retinal layer. Image from Willoughby, et al., 2010.  
  
Retina and Choroid 
 
The retina is found lining the inner surface of the eye—akin to wallpaper in 
a room. Light is transformed to a neural signal after being processed by different 
types of neurons that are found in the retina. These classes of cells are the 
photoreceptors (rods and cones), bipolar cells, horizontal cells, amacrine cells, 
ganglion cells, and glia (Mavlyutov & Guo, 2017). Careful arrangement of these 
cells results in ten identifiable and distinctly parallels layers. These layers are the 
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inner limiting membrane, nerve fiber layer, ganglion cell layer, inner plexiform 
layer, inner nuclear layer, outer plexiform layer, outer nuclear layer, outer limiting 
membrane, photoreceptor layer, retinal pigmented epithelium (Willoughby et al., 
2010). Each layer is attributed to the physical arrangement of the cells. As an 
example, the outer nuclear layer is where the nuclei of photoreceptor cells are 
found. Two notable structures are the inner limiting membrane (ILM), the 
innermost boundary between the retina and vitreous, and Bruch’s membrane 
(BM), a multilayered structure between the retinal pigmented epithelium and 
choriocapillaries (Klimanskaya, 2008; Remington, 2012). Retina thickness is 
often measured as the distance between the ILM and the BM/RPE interface 
(Grover, Murthy, Brar, & Chalam, 2010).  
 
Figure 2. Layers of the retina. Light travels through the various neural layers to 
reach the photoreceptors. Inner limiting membrane (ILM), nerve fiber layer (NFL), 
inner plexiform layer (IPL), inner nuclear layer (INL), outer plexiform layer (OPL), 
outer nuclear layer (ONL), outer limiting membrane (OLM), rods and cones layer 




Retina thickness varies depending on the structure of cells at the 
particular location. In the macula, which is largely responsible for the visual 
functions of the eye, the ganglion cell layer can be several cells thick. However, 
the surrounding retina has a ganglion cell layer that is only one cell thick, in 
comparison. The overall thickness decreases in the center of the macula, known 
as the fovea, where central vision is focused and is the sharpest (Willoughby et 
al., 2010).   
 
 
Figure 3. Macula and Optic Disc. The macula extends five disc diameters away 
from the optic disc. Center of the macula is the fovea. Image from Tabandeh & 




The two major types of light-sensitive photoreceptor cells are rods and 
cones. Largely found in the fovea, cones are able to detect green, blue, and 
yellow light. Rods, found peripheral to the fovea, are responsible for low light, 
non-color vision (Willoughby et al., 2010). A high demand for oxygen and 
nutrients, especially at the photoreceptor layer, makes the retina the most 
metabolically active tissue in the human body. The retina is dependent on two 
types of circulation to meet its metabolic needs: retinal and choroidal. 
Photoreceptors that are located along the outer retina depend on blood supply 
from the choroidal circulation to meet 90% of its needs (Linsenmeier & Zhang, 
2017). Cells on the inner retina, such as the ganglion, depend on retinal blood 
flow. 
Retina blood flow is auto-regulated by smooth muscle cells and pericytes 
that surround retinal arterioles to control vessel constriction (Kur, Newman, & 
Chan-Ling, 2012). Known as the myogenic response, the vessel diameter 
increases with a decrease in pressure to maintain blood flow. Not only is blood 
flow responsive to changes in pressure, but also it depends on the release of 
various factors and vasoactive substances, such as nitrous oxide and lactate. 
This allows for control over the amount of blood and metabolites that are 
delivered (Pournaras, Rungger-Brändle, Riva, Hardarson, & Stefansson, 2008). 
Retinal blood flow is affected by stimuli and disease states. For example, retinal 
vasculature has shown to constrict when the eye is stimulated with light 
(Pournaras & Riva, 2013). In diseased states such as proliferative diabetic 
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retinopathy, blood flow regulatory responses can become damped (Kur et al., 
2012).  
Whereas the myogenic response affects blood flow through retinal 
vasculature, choroidal vessels appear to show little response with changes in 
perfusion pressure. Blood flow in the choroid has also been shown to be less 
sensitive to changes in oxygen pressure. Interestingly, it has been measured that 
blood flow in the choroid is greater than in the retina, and less oxygen is 
extracted (Kur et al., 2012). Choroidal vessels are responsive to adrenergic 
neurotransmitters, signifying their dependence on input received from extrinsic 
autonomic innervation (Laties, 1967).  
 
Diabetic Retinopathy Pathophysiology  
	
Diabetes, a chronic disease in which the pancreas does not produce 
enough insulin or the body does not aptly respond to insulin, can lead to vision 
loss, nerve death, and kidney damage (World Health Organization, 2016). A 
major complication to diabetes is retinopathy—the world’s leading cause of 
blindness in patients aged 20 to 74. Globally, over 4 million people are projected 
to lose their sight due to diabetic retinopathy by 2025 (Tarr, Kaul, Chopra, 
Kohner, & Chibber, 2013).  
 Both Type I and Type II diabetes can cause diabetic retinopathy. The 
progression is particularly alarming because initial retinopathy can occur with 
little to no changes in vision. Diabetic retinopathy is characterized by vasculature 
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changes, microaneurysms, and dot blot hemorrhages that result from a 
pathological breakdown between the blood-retinal barrier (Heng et al., 2013). 
Other histological and clinically visible characteristics of diabetic retinopathy 
include basement membrane thickening, vascular leakage, apoptosis of retinal 
cells, inflammation, angiogenesis, neovascularization, and traction retinal 
detachment (Frank, 2004). As diabetic retinopathy progresses, there can be a 
continued leakage of plasma, leading to the accumulation of fluid in the macula. 
Swelling in the central retina is identified as diabetic macular edema. The re-
absorption of fluid can leave behind lipid and lipoproteins remnants in the form of 
hard exudates (Frank, 2004).  
Clinical grading of diabetic retinopathy is based on the original Early 
Treatment Diabetic Retinopathy Study (ETDRS) (Heng et al., 2013). The clinical 
grading levels include mild and moderate non-proliferative diabetic retinopathy 
(background diabetic retinopathy, severe non-proliferative diabetic retinopathy 
(pre-proliferative diabetic retinopathy), and non-high risk and high-risk 
proliferative diabetic retinopathy (proliferative diabetic retinopathy) (Heng et al., 
2013). Key characteristics in the grading classification of diabetic retinopathy are 






Figure 4, Top. Clinical grading of diabetic retinopathy. Key characteristics of 
diabetic retinopathy clinical grading. Image from Heng et al., 2013. Bottom. 
Visualizing the major pathway and differences between proliferative and non-




 Many mechanisms are involved in the manifestation of diabetic 
retinopathy. These include oxidative stress, polyol and hexosamine pathway 
activity, advanced glycation end-product formation and activation of protein 
kinase C isoforms (Heng et al., 2013). Hyperglycemia, oxidative stress, and 
activation of pro-inflammatory pathways induce inflammation in vascular 
endothelial cells. Inflammation causing the continued extravasation of leukocytes 
is hypothesized to cause the continued breakdown of the retinal-blood barrier in 
diabetic patients (Kusuhara, Fukushima, Ogura, Inoue, & Uemura, 2018). As a 
result, there are currently efforts to create antibody drugs that target these 
inflammatory signals.  
Shifts in thinking have also guided the perception of diabetic retinopathy 
as a retinal ischemia. It has been demonstrated that microaneurysms and 
intraretinal hemorrhages that occur in pre-proliferative retinopathy leads to tissue 
ischemia (Frank, 2004). Since the retina is a tissue with tremendous metabolic 
needs, it becomes vulnerable when faced with dramatic reductions in oxygen 
supply (Arden & Sivaprasad, 2011). This makes the retina particularly 
susceptible to ischemia. As a result of hypoxia, retinas in diabetic retinopathy 
patients release pro-angiogenic signals, such as vascular endothelial growth 
factor (VEGF). VEGF promotes retinal neovascularization, which attempts to 
increase local blood supply yet concurrently increases the likelihood for future 





Complication: Diabetic Macular Edema 
Between 2.7-11% of patients with diabetic retinopathy will have diabetic 
macular edema (DME)—retinal thickening due to fluid buildup. It is the most 
common cause for vision loss in diabetic retinopathy patients. An early ETDRS 
report showed that the rate of moderate vision loss from DME is at 8% per year 
with worse eyes losing vision at an even faster rate (Browning, Stewart, & Lee, 
2018).  
There are several classifications within diabetic macular edema. Typically, 
diabetic macular edema signifies retinal thickening or the buildup of hard 
exudates within an optic disc’s diameter away from the macula. Once diabetic 
macular edema involves the fovea, it is considered center-involved DME. 
Clinically significant macular edema (CSME) is when one of the following criteria 
are met: (1) retinal thickening to 500 µm or greater at the macula center (2) hard 
exudates within 500 µm of the macula coupled with surrounding retinal thickening 
(3) Retinal thickening the size of the optic disc within one optic disc diameter’s 
distance from the macula (Early Treatment Diabetic Retinopathy Study Group, 
1985).  
In DME, the buildup of extracellular fluid in the macula can be explained 
by the oxygen theory (Stefánsson, 2006). Hyperglycemia due to diabetes causes 
decreased inner retina perfusion, and consequently, decreased oxygen delivery. 
This causes retinal arterioles to dilate due to autoregulatory responses, which 
increases the intravascular pressure. Heightened hydrostatic pressure within 
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retinal capillaries facilitates exudation of fluid into the extracellular space. Since 
the RPE pumps that are normally responsible for resorbing extracellular fluid can 
no longer keep up, there results in net fluid accumulation, or macular edema 
(Stefánsson, 2006).  
 Cytokines that are produced in response to hypoxia can also potentiate 
the formation of DME. VEGF, which is produced in response to low oxygen 
tension, increases vascular permeability not only to fluid, but also to leukocytes. 
To reduce permeability, intravitreal anti-VEGF injections are used to block VEGF. 
Corticosteroids are also used to reduce VEGF gene expression. (Browning et al., 
2018).  
 
Diabetic Retinopathy Disease Monitoring  
Imaging 
 
Imaging is of utmost importance in managing and monitoring diabetic 
retinopathy and DME. Optical Coherence Tomography (OCT) is particularly 
useful for providing a cross-sectional image as well as its ability to measure 
retinal thickness and calculate retinal volume. The working mechanism behind 
OCT involves two near-infrared beams that are aimed at the retina and choroid. 
An interference pattern between the two light beams is then created depending 
on the thickness and reflectance of various eye structures (Frank, 2004). This 
pattern can then be constructed into an image that provides a cross-sectional 
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view of the retina. DME can easily be viewed through this simple and quick 
imaging technique.  
 
Figure 5. Diabetic Macular Edema viewed through Optical Coherence 
Tomography. OCT allows for cross-sectional visualization of the retina along 
with features to show the retinal thickness as both a heat map and by subfields. 
On the left is a retina with DME compared to a healthy retina on the right (Frank, 
2004).  
	
 OCT is also useful for its high reproducibility. It has been determined that 
changes in central subfield thickness that are greater than 11% are likely 
significant (Diabetic Retinopathy Clinical Research Network, 2007). Even when 
there are changed intraocular opacities such as cataracts and vitreous 
hemorrhage, the variability remains small (Frank, 2004). Its high test-retest 
variability combined with the feature to take follow up images at a consistent 
location makes it an effective tool for disease monitoring and for research (Heng 




Visual acuity is the most common method to determine visual function 
(Colenbrander, 2001). It tests the subject’s ability to identify correctly the smallest 
detail possible, such as a letter or its direction.  
Visual acuity is measured monocularly with patients reading the chart from 
the largest figures to the smallest possible. The smallest row of letters that can 
be read accurately is the visual acuity. Herman Snellen introduced his famous 
chart in 1862 along with a ubiquitously used Snellen notation. The notation 
consists of two numbers, say 20/40, which signifies that what a patient can read 
at 20 feet, a person with normal vision can do at 40 feet. Hence, normal vision is 
described as 20/20.  
Since Snellen introduced his famous chart in 1862, further developments 
have been made to improve accuracy in visual acuity charts. Bailey-Lovie charts 
improved upon Snellen’s by standardizing each line to have five letters and also 
formulating a logarithmic progression in decreasing font size. This gave way to 
the LogMAR measurement: measuring the minimum angle that is required to 
resolve details. For example, a patient who can see details that are 1 minute of 
visual angle has a Log(1), which is equal to LogMAR of 0. Someone who can 
only see details that are 2 minute of visual angle has a LogMAR of 0.3 (Log(2) = 
0.3). This notation is particularly useful because LogMAR decreases in a linear 




The equation to convert between LogMAR to Snellen units is: 
 
𝐿𝑜𝑔𝑀𝐴𝑅 =  −20(
20
𝑑𝑖𝑠𝑡𝑎𝑛𝑐𝑒 𝑜𝑓 𝑏𝑒𝑠𝑡 𝑙𝑖𝑛𝑒 𝑟𝑒𝑎𝑑 𝑖𝑛 𝑓𝑒𝑒𝑡) 
 
Table 1. Converting Between Snellen and LogMAR Visual Acuity 
Measurements. LogMAR calculations based on the equation 1. LP = eye can 
only detect the presence of light; HM = eye can only detect close hand 
movements CF = eye can see the number of fingers held at a distance closer 
than the visual acuity chart 
Snellen Visual Acuity (Feet) LogMAR 
Light Perception (LP) 2.60 
Hand Motion (HM) 2.30 
















Sloan charts optimized testing reliability by utilizing letters that are 
identified at a similar percentage in visual acuity testing (Alexander, Xie, & 
Derlacki, 1997). The ETDRS visual acuity system, built on the logMAR scale and 
utilizes Sloan letters, further improved testing accuracy by printing letters on a 
square footprint instead of a rectangle. Importantly, ETDRS has also established 
visual acuity measurement protocols for studying visual acuity changes in 




Whereas visual acuity signifies how large an object must be to be seen, 
contrast sensitivity measures how much contrast must be present before it is 
apparent (Rosenthal & Fischer, 2014). It is our eye’s ability to distinguish patterns 
of light and dark—often of similar shade (Beckley, 2016). Measuring contrast 
sensitivity has been particularly useful in occupational health where it gleans 
real-world vision performance that might not be measured by visual acuity. For 
instance, daily activities such as driving, balance, and reading all rely on 
differentiating dark and light stimuli. It is contended that visual acuity and contrast 
sensitivity should be used in conjunction to determine visual function, and also 
visual impairment. Interpreting visual performance using these two measures 




The sensitivity of contrast sensitivity measurement makes it a useful tool 
to detect subtle changes in vision. There are several clinical examples where 
diseases cause decrease in contrast sensitivity although visual acuity maintains 
constant. This occurs in patients after refractive surgery, with optic neuritis and 
multiple sclerosis, and in diabetics with minimal retinopathy (Safi, Safi, Hafezi-
Moghadam, & Ahmadieh, 2018). Changes in contrast sensitivity has also been 
shown to demonstrate predisposition to age-related macular degeneration when 
no changes in visual acuity have been measured (Stangos, Voutas, Topouzis, & 
Karampatakis, 1995). Additionally, it can also a useful tool to detect changes in 
visual performance in those with severe visual impairments (Bittner, Jeter, & 
Dagnelie, 2011).  
The main principle behind determining contrast sensitivity is finding the 
minimum contrast that can be distinguished against a background, or the 
contrast threshold. The reciprocal of the contrast threshold is contrast sensitivity 
(Emergent Techniques for Assessment of Visual Performance, 1985). Contrast 
sensitivity tests serve to find the minimum difference in signal a subject can 
identify.  
It is important to note that contrast sensitivity is dependent on how 
detailed the edges of a stimuli are. The detail can be quantified by spatial 
frequency, or number of stimuli per visual angle. When looking at coarser details, 
or low spatial frequency, the contrast sensitivity can differ compared to looking at 
finer details, or high spatial frequency. We tend to be most sensitive to signals 
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that have a spatial frequency within 2 to 5 cycles to degree. Contrast sensitivity is 
lower at both lower spatial frequencies, and at higher spatial frequencies 
(Emergent Techniques for Assessment of Visual Performance, 1985). 
While there are numerous approaches to testing, sinusoidal gratings have 
emerged effective in capturing different contrast sensitivities at different spatial 
frequencies. A contrast sensitivity function can be obtained by plotting contrast 
sensitivity against spatial frequency.  
 
Figure 6. Contrast Sensitivity Function. The ability to tell apart contrast 
(contrast sensitivity) depends on how many stimuli there are per visual angle 
(spatial frequency). Image from Emergent Techniques for Assessment of Visual 




This makes a grating based test, such as the CSV-1000E, more 
encompassing test because it tests contrast sensitivity at different spatial 
frequencies.  
Understanding the contrast sensitivity function also reveals limitations in 
only testing for visual acuity. Since visual acuity charts tend to printed with detail 
and at high contrast, it only tests for vision at high spatial frequencies (Emergent 
Techniques for Assessment of Visual Performance, 1985). When only visual 
acuity is used for fundamental vision evaluation and for legal screening, it fails to 




Intraocular pressure measurements are often done routinely to screen for 
glaucoma, monitor post-operative changes, and signify changes to the eye 
(Stevens, Gilbert, & Astbury, 2007). In non-proliferative diabetic retinopathy, it 
has been observed that subjects with higher blood sugar indicators, hemoglobin 
A1c, have higher intraocular pressures (Hymowitz, Chang, Feinberg, & Roy, 
2016). It is hypothesized that higher glucose levels in the anterior chamber 
accelerates the accumulation of extracellular matrix, which impedes aqueous 
outflow and increases pressure. IOP is also worth monitoring as increased IOP 
have been observed in patients receiving anti-VEGF and pan retinal 






Pan Retinal Photocoagulation (PRP) is a major treatment method for 
proliferative diabetic retinopathy. The procedure is generally performed in an 
outpatient setting on patients with dilated pupils and topical anesthetics. A laser 
is applied to the retina through either a slit lamp or an indirect ophthalmoscope. 
Typically, a green or yellow laser is applied for 0.07 to 0.1 seconds to create a 
laser burn lesion of 500 micrometers. There can be 1200 to 1600 laser burns in a 
procedure, where the burns are spaced approximately one lesion’s width apart 
from each other (Figure 7) (Bressler, 2011).  
The laser is not applied to neovascularization, but rather to pigment 
epithelial cells. Absorption of laser light by cells in the outer retina promotes their 
destruction. Oxygen availability is increased as the hypoxic pigmented rods and 
cones are destroyed, increasing oxygen availability elsewhere (Bressler, 2011). 
Cells in the outer retina then become better perfused due to greater accessibility 
to blood in the choriocapillaries. A decreased demand for oxygen leads to less 
release of hypoxic factors, including VEGF-A. This is the potential cause of 
slower angiogenesis, and even regression in blood vessel growth. An ETDRS 
study showed that PRP led a 50% decrease in moderate vision loss in patients 




Figure 7. Pan Retinal Photocoagulation (PRP). Visible lesions in the peripheral 
retina from PRP treatment. Image from Beth Israel Deaconess Medical Center. 
 
 Although it is a well-established treatment method, PRP does come with 
notable side effects including decreased night vision and augmented pre-existing 
macular edema (Das, Stroud, Mehta, & Rangasamy, 2015). The therapy 
continues to evolve. Efforts have been made to decrease patient pain by using 
shorter durations of laser but at higher power. Various studies have also 
attempted to reduce the effects of vision loss and macular edema (Muqit, 2010).  
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 A second treatment method for diabetic retinopathy involves targeting 
elevated VEGF levels by administering anti-VEGF antibodies. VEGF increases 
capillary permeability, which allows for the extravasation of fluid and leukocytes 
at retinal blood vessels (Das et al., 2015). These anti-VEGF antibodies reduce 
the characteristic angiogenesis in patients with diabetic retinopathy. Drugs that 
target the VEGF molecule include full-length antibodies (bevacizumab), 
monoclonal antibody fragments (ranibizumab), and fusion protein (aflibercept) 
(Avery et al., 2017). Anti-VEGF drugs are indicated for diabetic edema involving 
the center macula while laser treatment is indicated for diabetic macular edema 
found elsewhere in the peripheral macula and retina (Das et al., 2015).  
 Although anti-VEGF drugs have been demonstrated to stop disease 
progress and improve vision, it comes with risk and potential for adverse events. 
Endophthalmitis, intraocular infection that can potentially cause loss of vision, 
has an incidence rate of 0.0019 to 1.6% per patient undergoing anti-VEGF 
therapy (Falavarjani & Nguyen, 2013). Patients also face the risk of intraocular 
inflammation, developing or progressing retinal detachment, and IOP elevation.  
 Anti-VEGF treatment has also shown to be a costly. Although efficacy 
between anti-VEGF and PRP treatments remain similar, it has been calculated 
that anti-VEGF therapy costs $16,849 for each line of vision improvement, 
compared to $725 for PRP (Zhao & Singh, 2018).  
Vitrectomy, surgery to remove parts or all of the vitreous, is another 
method to treat diabetic retinopathy. It is hypothesized that the vitreous can serve 
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as a VEGF reservoir, and is better off removed (Heng et al., 2013). In patients 
with macular edema and macular traction caused by persistent adherence of the 
retina to the vitreous, removing the vitreous allows the macula to return to a more 
normal state. However, the 26% rate of vision gain with surgery is weighed 
against a 22% risk of vision loss (Heng et al., 2013).  
 
Figure 8. Schematic of Diabetic Macular Edema Treatment Methods. Image 




 As diabetic retinopathy is perceived as a retinal ischemia condition, efforts 
have been made to increase oxygen delivery to the retina. In retinal detachment, 
another condition involving retinal ischemia, providing supplemental oxygen has 
been shown to reduce photoreceptor death in feline models (Mervin et al., 1999). 
In other models of feline retinal detachment, hyperoxia has been shown to 
increase oxygen consumption in detached retina, which suggests improvement in 
photoreceptor survival (Wang & Linsenmeier, 2007). Improving photoreceptor 
survival and reducing their death suggests that oxygen maybe an effective 
treatment method to minimize vision loss in retinal ischemia.  
 One pilot study attempted to study the use of supplemental oxygen for 
diabetic macular edema. Five patients with DME were placed on oxygen for three 
months and saw foveal thickness decrease an average of 43.5%. Four of the ten 
eyes saw improvements in visual acuity of more than a line (Nguyen et al., 2004). 
In a different study on hyperoxia, patients with diabetic retinopathy who breathed 
100% oxygen for 15 minutes saw an improvement in contrast sensitivity at a 
spatial frequency of 12 cycles per degree (Harris et al., 1996). These studies 
suggest that hyperoxia for an extended duration can reduce edema, and even at 









Figure 9. Oxygen Tension and Edema. Schematic showing the pathways 
involved in decreasing edema with increased oxygen in the inner retina. Image 







Specific Aims and Objectives 
The goals of this study were to investigate the anatomical changes and 
visual performance outcomes of supplemental oxygen therapy for patients with 
diabetic retinopathy. We first hypothesized that a three-hour session of 
normobaric oxygen therapy would decrease macular edema, leading to anatomic 
normalization. In addition, we hypothesized that normobaric oxygen treatment 
would improve visual performance through indicators such as visual acuity and 
contrast sensitivity. We believe this study contributes to the understanding of how 
hyperoxia can be used as a treatment for ocular ischemic disorders such as 






Patients diagnosed with diabetic retinopathy were invited to participate in 
a three-hour normobaric oxygen study, which was conducted at the Beth Israel 
Deaconess Medical Center Eye Clinic in Boston Massachusetts. All participants 
proceeded with the study after signing an informed consent that was reviewed 
and approved by an institutional review board.  
 
Inclusion Criteria 
All patients were recruited from the Eye Clinic at Beth Israel Deaconess 
Medical Center and are patients of Dr. Jorge Arroyo. All of the patient-subjects 
presented with diabetic retinopathy in at least one eye on their most recent 
ophthalmic exam. In order for patients to qualify for the study, they also had to be 
at least 18 years of age and present with macula edema with a macula central 
point thickness of at least 275 microns in at least one eye as determined by 
Heidelberg OCT. Furthermore, patients must also have clear media, capacity for 
pupillary dilation, and be able to cooperate for OCT imaging and fundus 
examination. Subjects must also be able and willing to provide informed consent. 
Any patient with a history of smoking or pulmonary-related conditions was not 
recruited for the study.  
The control group was selected retroactively from patient-subjects who 
received identical 3-hour normobaric oxygen treatment, but for typically unilateral 
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ocular conditions such as retinal detachment. From this group of patients, we 
used the data gathered from the healthy eyes of diabetic patients as our control.  
 
Oxygen Delivery 
Patient-subjects received oxygen by either an Everflo Oxygen 
Concentrator 5 LPM (Phillips Respironics, USA) or a cylindrical oxygen tank. 
Oxygen was delivered to the patient at a flow rate of 5 liters per minute at 
atmospheric pressure and breathed through a Simple Concentration Oxygen 
Mask (Allied Healthcare, USA). Upon beginning oxygen treatment, the start time 
was recorded on the patient chart to ensure a consistent three-hour trial with 
each subject.  
 
Measurements of Visual Performance 
ETDRS 
Visual acuity was measured via the ETDRS visual acuity system before 
and after subjects received oxygen. Subjects read from the Original Series 
ETDRS Chart R (Precision Vision, Woodstock, IL, USA) placed 4 meters (13.12 
feet) away in an ETDRS Illuminator Cabinet (Precision Vision, Woodstock, IL, 
USA) that provided a standardized retro illumination at 85 candelas per square 
meter with all other light sources turned off. Each eye was tested independently 
using an occluder. Visual acuity was recorded in Snellen notation, and later 
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converted to LogMAR for analysis. Correctly identifying 3 out of 5 letters within a 
row permitted patients to attempt reading the subsequent row. Subjects who 
used corrective lenses wore them for both before and after measurements. All 
patients also tested with a pinhole refraction to approximate for the best 
corrected visual acuity (BCVA).  
Patients were not dilated until all the follow up tests of the oxygen trial 
were completed. An ETDRS study discovered that best corrected visual acuity 
declines with pupillary dilation, with a median decrease of 3 letters and large 
variability as changes ranged from a 12 letter gain to a 25 letter loss. Usually, 
only 2% of subjects are expected to see a difference of more than 10 letters 
according to test-retest reliability experiments (Sun et al., 2009). Thus the 
protocol was written to avoid variability that comes with pupillary dilation by 
postponing it until the end of the study.  
Contrast Sensitivity  
Patient subjects were also assessed for contrast sensitivity immediately 
before and after receiving oxygen treatment. Contrast sensitivity was measured 
using the CSV-1000E (Vector Vision; Dayton, OH, USA) chart. Similar to the 
ETDRS chart, this translucent chart is also retro-illuminated at a standardized 
luminance at 85 candelas per square meter. In comparison to other contrast 
sensitivity chart types, the CSV-1000E is unique in its ability to test four spatial 
frequencies (3, 6, 12, and 18 cycles per degree). The test works via a two-
alternative quasi-forced choice procedure—the steps are explained below. This 
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chart was selected in particular for its test-retest stability in measuring contrast 
sensitivity in diseased eyes (Pomerance & Evans, 1994). Furthermore, marginal 
improvement in contrast sensitivity has also been shown in patients with early 
diabetic retinopathy who are receiving oxygen therapy (Harris et al., 1996).  
Each eye is tested independently without pinholes. Patients are asked to 
compare two circles within a selection and determine whether the “top” or 
“bottom” circle contains the grated pattern. The test continues across the row 
following each correct selection as contrast decreases, signifying greater contrast 
sensitivity. When a patient is having difficulty making a selection, they are 
permitted more time to stare and make a best guess. Once there is a wrong 
selection or a patient states that there is no difference between the two circles, 
the test proceeds to the next row. The spatial frequency increases with each row. 
Failure to identify the first selection results in asking the patient whether they can 






Figure 10. CSV-1000E chart and marking sheet. Patients determine whether 
the grated pattern are in the top or bottom of each selection. Contrast decreases 
across each row, and spatial frequency increases with each row (Top). Correct 
and incorrect selections are marked on the scoring sheet (below) that creates a 
contrast sensitivity function curve. Images from VectorVision.   
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Table 2. Corresponding CSV-1000E selections to contrast sensitivity 
measurements (log units). Cpd = cycles per degree.  










8 2.09 2.30 2.00 1.56 
7 1.94 2.15 1.85 1.41 
6 1.79 2.00 1.70 1.26 
5 1.64 1.85 1.55 1.11 
4 1.49 1.70 1.40 0.96 
3 1.34 1.55 1.25 0.81 
2 1.17 1.38 1.08 0.64 
1 1.00 1.21 0.91 0.47 
0 0.70 0.91 0.61 0.17 
 
Intraocular Pressure 
The intraocular pressure of subject eyes was measured both before and 
after receiving oxygen treatment. Subjects first received a drop of 0.5% 
proparacaine hydrochloride ophthalmic solution (Sandoz, Holzkirchen, 
Germany). Intraocular pressure was then measured by a handheld applanation 
tonometer—either the Tono-Pen or Tono-Pen XL model (Reichert, Buffalo, New 
York). The same device was used for pre-oxygen and post-oxygen 
measurements. As technique is important in acquiring an accurate reading, it 
was ensured that the probe tip was held perpendicularly to the eye and within 0.5 
inch from the cornea as advised in the device’s instructional manual.  
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Measurement of Anatomic Changes  
Optical Coherence Tomography was performed on the Heidelberg 
Spectralis OCT imaging platform. Each patient eye was scanned using a series 
of scan patterns: vertical line scan, horizontal line scan, star scan, 7-line scan, 
and fast raster scan. A report is generated using the fast-raster scan, which 
analyzes macular thickness in nine subfields. However, the macular thickness, 
which is the distance between the internal limiting membrane and Bruch’s 
membrane, can be miscalculated if the imaging software does not properly 
identify either boundary. Manual corrections were made when the software was 
unable to trace either boundary correctly. Each image was then set as a 
reference, allowing subsequent images to be taken at the same location, 
permitting for direct comparison and analysis.  
 After patients completed their oxygen treatment, the same OCT protocol 
was repeated. Each image was taken as a “Follow-Up” allowing the machine to 
image in the same location as it did pre-oxygen. Following manual correction if 
needed, a thickness change profile was generated. This showed the change in 
macular thickness between the before and after images. The thickness change 
analysis also displayed change in thickness within each of the nine macular 
subfields.  
 Two sets of analysis were completed for determining changes in retinal 
thickness. One was based upon the measurements from the central subfield of 
an OCT scan, central macular thickness (CMT). The central subfield is where the 
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fovea is located. The other involved manually identifying the initial point with 





Statistical analyses were performed using Microsoft Excel 2013 and R 
Studio. Before oxygen and after oxygen measured to determine the changes in 
both diabetic retinopathy eyes and control eyes. The control group consisted of 
healthy eyes from diabetic patients without retinopathy. Average changes in 
macular edema (percent change in CMT and MMT), visual acuity (LogMAR), 
contrast sensitivity (log units), and IOP (mmHg) were calculated along with the 
95% confidence, and p-value.  
Significance, when calculated p-values were less than 0.05, was 
determined by two-sample, two-tailed Welch t-tests. The two groups that were 
compared in the t-tests were the differences in the diabetic macular edema group 
(before and after oxygen) with the differences in the control group (before and 
after oxygen). T-tests performed on the control group used a different strategy by 
directly comparing the measurements before and after oxygen. Figures were 









Fifty-one three-hour normobaric hyperoxia trials were completed for 
patients with diabetic retinopathy. Ten out of the 102 eyes were excluded for 
having incomplete OCT measurements or presented with additional ocular 
conditions that would be a confounding variable. The remaining 92 eyes with 
diabetic macular edema were used to determine the anatomical effects of 3-hour 
normobaric oxygen.  
 Change in visual performance was a secondary study objective that was 
integrated later to the study. Of the trials completed, 13 eyes from 9 patients had 
complete before and after visual performance data and an initial vision worse 
than 20/32. These eyes were analyzed for changes in visual performance.  
11 healthy eyes from diabetic patients who presented without retinopathy 
are used as the control. These patient-subjects completed a 3-hour normobaric 
oxygen trial for a unilateral ocular condition, such as retinal detachment, and had 
complete before and after OCT, visual performance, and intraocular pressure 
measurements.   
In anatomical changes, eyes with diabetic retinopathy exhibited a maximal 
macular thickness (MMT) change by an average of -2.093% (p < .05; 95% CI  
-1.350% to -3.011%). For comparison, control eyes increased in retinal thickness 
by a mean of 0.136% (p = .645; 95% CI -0.774% to 0.502%) after undergoing the 
trial. The central macular thickness (CMT) changed by an average of -0.88% (p < 
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.05; 95% CI -0.569 to -1.308%). Control eyes experienced an insignificant 
change of 0.057% in CMT for comparison (p = 0.642; 95% CI -0.326% to 
0.211%) (Figure 11).   
Patients saw an improvement in visual acuity as well. On average, 
patients with diabetic retinopathy experienced an average LogMAR change of -
0.043 (p < 0.05; 95% CI -0.007 to -0.079). Noting that a lower LogMAR indicates 
better visual acutity, this signifies approximately a gain of two letters. With an 
average LogMAR change of 0.03 (p = .640; 95% CI -0.01 to 0.07), healthy eyes 
experienced a non-significant change in visual acuity.  
 However, changes in contrast sensitivity were indeterminant. In both 
diabetic retinopathy subjects and healthy controls, contrast sensitivity did not 
change a significant amount at the four measured spatial frequencies.  
Intraocular pressure also had a less noticeable change. For patients with 
diabetic retinopathy, the mean difference in IOP was 0.6 mmHg (p = .647; 95% 
CI -0.13 to 1.33 mmHg). This is compared to a mean IOP difference of 1 mmHg 
(p = .703; 95% CI -1.38 to 3.38 mmHg) in healthy controls that also underwent 









Figure 11. Change in macular thickness with oxygen. Comparing the change 
in macular thickness at the central subfield (Central Macular Thickness, top), and 
tracking the point with greatest initial macular thickness (Maximal Macular 





Table 3. Results of Macular Thickness, Visual Acuity and Intraocular 
Pressure from 3-Hour Hyperoxia Trial 
  Mean 95% CI P-Value 
Maximal Macular 
Thickness (MMT) ,% 
DME -2.093 -1.35, -3.011 0.000007 
Healthy 0.136 -0.774, 0.502 0.645 
Central Subfield 
Thickness (CMT), % 
DME -0.88 -0.569, -1.308 0.000007 
Healthy 0.057 -0.326, 0.211 0.642 
Visual Acuity 
(LogMAR) 
DME -0.043 -0.007, -0.079 0.025 
Healthy 0.03 0.07, -0.01 0.640 
IOP DME 0.6 -0.13, 1.33 0.647 
Healthy 1 -1.38, 3.38 0.703 
 
 
Table 4. Changes in Contrast Sensitivity.  
Contrast Sensitivity (Log Units) 





95% CI P-Value 
Average 
Change 
95% CI P-Value 
3 0.061 -0.102, 0.224 0.843 0.100 -0.080, 0.280 0.277 
6 0.000 -0.113, 0.113 0.759 0.028 -0.074, 0.131 0.859 
12 -0.026 -0.189, 0.137 0.943 0.028 -0.123, 0.180 0.907 







In this study, we examined the anatomical and visual performance 
changes from hyperoxia treatment in diabetic macular edema (DME). Breathing 
normobaric oxygen at 5 liters per minute, diabetic retinopathy subjects saw both 
the maximal macular thickness (MMT) and central macular (CMT) thickness 
decrease significantly (p < .05) by an average of 2.09% and 0.88%, respectively. 
The effects of hyperoxia in reducing edema becomes apparent when comparing 
to the healthy control group that experienced an average of 0.136% increase in 
MMT and 0.057% increase in CMT.  
A previous study (Nguyen, 2004) demonstrated that six months of 
supplemental oxygen therapy led to a significant decrease in diabetic macular 
edema. Retina thickness at the fovea reduced an average of 43.5% in that study. 
Our study, which involved oxygen therapy for only three hours, saw smaller, but 
still significant decrease in macular thickness.   
Our results continue to support the oxygen theory in that macular edema 
stems from retinal ischemia. It is believed that due to autoregulation, increasing 
retinal oxygenation causes vessel vasoconstriction and decreased production of 
VEGF. Consequently, less hydrostatic pressure in the arteries leads to less 




Further research is required to explain the results of our study. First, 
retinal blood flow analysis should be conducted at different levels of oxygenation 
to observe how blood flow and pressure changes with hyperoxia. The 
biochemical pathways underpinning macular edema should be analyzed in their 
response to oxygen. For example, understanding how VEGF production changes 
in different levels of retinal oxygenation can support the use of oxygen in 
combination therapy. This can potentially accentuate the effects of anti-VEGF 
drugs. Utilizing anti-VEGF drugs in conjunction with oxygen therapy could also 
potentially decrease the numbers of anti-VEGF injections, which may reduce 
rates of infection and decrease cost of care.  
The overall effects of hyperoxia on visual performance were indeterminate 
in our study. Visual acuity did increase on average by -0.043 (p < 0.05) LogMAR 
units in the diabetic retinopathy group compared to a 0.3 (p > 0.05) LogMAR unit 
decrease in the control group. 10 out of the 13 diabetic eyes improved in visual 
acuity. For comparison, 4 out of 10 eyes improved in the Nguyen (2004) study. It 
is worth pointing out that pinhole occluder testing was used in our study to 
determine best-corrected visual acuity instead of other established refraction 
methods, such as autorefraction or manual refraction. An ETDRS study found 
pinhole refraction to have significantly greater test-retest variability than the gold 
standard manual refraction method (Sun et al., 2011). 
It is also worthy to note that while diabetic macular edema is the number 
one cause for vision loss in diabetic retinopathy, total retinal thickness is not the 
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best predictor of visual acuity (Wong, Lee, Yau, & Wong, 2015). A previous study 
by Wong (2014) found the correlation coefficient between total retinal thickness 
and visual acuity to be 0.34 (p < 0.001) whereas the correlation coefficient 
between outer retinal thickness and visual acuity to be 0.65 (p < 0.001) (Wong et 
al., 2015). Measured as the distance between the RPE and external limiting 
membrane, the outer retinal thickness may indicate photoreceptor viability. Thus 
it is worth exploring the effects of hyperoxia on specifically outer retinal thickness. 
The direct effects of oxygen on photoreceptors should be investigated given our 
results of increased visual acuity with hyperoxia.  
Contrast sensitivity, the other measure for visual performance, saw no 
significant changes across all spatial frequencies in diabetic eyes. These results 
add to the results of Harris’ (1996) study in which no difference in contrast 
sensitivity was observed between hyperoxic diabetic and healthy eyes. In that 
study however, a significant improvement was observed between diabetic 
patients on room air versus those on oxygen at a spatial frequency of 12 cycles 
per degree. All in all, hyperoxia revealed little to no change in contrast detection 
ability for those with DME.  
 With our evidence that normobaric oxygen over three hours can reduce 
edema and improve visual acuity supports that diabetic retinopathy and diabetic 
macular edema are inherently ischemic conditions. This brings up the idea that 
oxygen therapy should be investigated for other retinal ischemia conditions, such 
as retinal vein occlusions and retinal artery occlusions. Other future directions 
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can also involve investigating the long-term effects and usage of oxygen. As 
mentioned, increasing retinal oxygenation can potentially supplement anti-VEGF 
injections. It can also potentially serve to address the side effect of retinal edema 
that comes with panretinal photocoagulation (PRP). And while the effects of 
oxygen over three hours are encouraging, we should set out to investigate the 
effects of oxygen with longer duration. Not only will that make the evidence we 
have gathered more robust, it can also reveal more drawbacks that come with 
long-term oxygen use, whether that is increased toxicity or heightened likelihood 
to develop other conditions such as cataracts. In addition, further research can 
be completed on determining dosing, and qualifying how much oxygen needs to 
be delivered to see the greatest results.  
 To conclude, we have demonstrated that short-term normobaric hyperoxia 
has significant effects in retinal anatomical normalization and improving visual 
acuity. These effects as observed through increased retinal oxygenation further 
suggest the oxygen theory behind diabetic retinopathy, and that oxygen could be 
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